These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19847626)

  • 1. Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis.
    Yang Y; Tsifansky MD; Wu CJ; Yang HI; Schmidt G; Yeo Y
    Pharm Res; 2010 Jan; 27(1):151-60. PubMed ID: 19847626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients.
    Akdag Cayli Y; Sahin S; Buttini F; Balducci AG; Montanari S; Vural I; Oner L
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1378-1389. PubMed ID: 28420285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model.
    Yang Y; Tsifansky MD; Shin S; Lin Q; Yeo Y
    Biotechnol Bioeng; 2011 Jun; 108(6):1441-9. PubMed ID: 21488050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis.
    Lababidi N; Ofosu Kissi E; Elgaher WAM; Sigal V; Haupenthal J; Schwarz BC; Hirsch AKH; Rades T; Schneider M
    J Control Release; 2019 Nov; 314():62-71. PubMed ID: 31654686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhalable DNase I microparticles engineered with biologically active excipients.
    Osman R; Al Jamal KT; Kan PL; Awad G; Mortada N; El-Shamy AE; Alpar O
    Pulm Pharmacol Ther; 2013 Dec; 26(6):700-9. PubMed ID: 23933140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry powder inhalation containing muco-inert ciprofloxacin and colistin co-loaded liposomes for pulmonary P. Aeruginosa biofilm eradication.
    Wang J; Guo Y; Lu W; Liu X; Zhang J; Sun J; Chai G
    Int J Pharm; 2024 Jun; 658():124208. PubMed ID: 38723731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation and process development of (recombinant human) deoxyribonuclease I as a powder for inhalation.
    Zijlstra GS; Ponsioen BJ; Hummel SA; Sanders N; Hinrichs WL; de Boer AH; Frijlink HW
    Pharm Dev Technol; 2009; 14(4):358-68. PubMed ID: 19552563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of PEGylation on the mucolytic activity of recombinant human deoxyribonuclease I in cystic fibrosis sputum.
    Guichard MJ; Kinoo D; Aubriot AS; Bauwens N; Gougué J; Vermeulen F; Lebecque P; Leal T; Vanbever R
    Clin Sci (Lond); 2018 Jul; 132(13):1439-1452. PubMed ID: 29871879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
    Lin Y; Chang RYK; Britton WJ; Morales S; Kutter E; Li J; Chan HK
    Eur J Pharm Biopharm; 2019 Sep; 142():543-552. PubMed ID: 31398437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gentamicin and leucine inhalable powder: what about antipseudomonal activity and permeation through cystic fibrosis mucus?
    Russo P; Stigliani M; Prota L; Auriemma G; Crescenzi C; Porta A; Aquino RP
    Int J Pharm; 2013 Jan; 440(2):250-5. PubMed ID: 22683456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.
    Adi H; Young PM; Chan HK; Agus H; Traini D
    Eur J Pharm Sci; 2010 Jun; 40(3):239-47. PubMed ID: 20371286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disassembling bacterial extracellular matrix with DNase-coated nanoparticles to enhance antibiotic delivery in biofilm infections.
    Baelo A; Levato R; Julián E; Crespo A; Astola J; Gavaldà J; Engel E; Mateos-Timoneda MA; Torrents E
    J Control Release; 2015 Jul; 209():150-8. PubMed ID: 25913364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and characterization of a spray-dried inhalable ternary combination for the treatment of Pseudomonas aeruginosa biofilm infection in cystic fibrosis.
    Alhajj N; Yahya MFZR; O'Reilly NJ; Cathcart H
    Eur J Pharm Sci; 2024 Jan; 192():106654. PubMed ID: 38013123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antibacterial effect of inhaled aztreonam and tobramycin fixed dose combination to combat multidrug-resistant Gram-negative bacteria.
    Wang J; Kutter JP; Mu H; Moodley A; Yang M
    Int J Pharm; 2020 Nov; 590():119877. PubMed ID: 32927003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: Spray drying versus spray freeze drying preparation.
    Yu H; Teo J; Chew JW; Hadinoto K
    Int J Pharm; 2016 Feb; 499(1-2):38-46. PubMed ID: 26757148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
    Stass H; Delesen H; Nagelschmitz J; Staab D
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microparticles for inhalational delivery of antipseudomonal antibiotics.
    Tsifansky MD; Yeo Y; Evgenov OV; Bellas E; Benjamin J; Kohane DS
    AAPS J; 2008 Jun; 10(2):254-60. PubMed ID: 18454321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
    J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spray-dried multidrug particles for pulmonary co-delivery of antibiotics with N-acetylcysteine and curcumin-loaded PLGA-nanoparticles.
    Lababidi N; Montefusco-Pereira CV; de Souza Carvalho-Wodarz C; Lehr CM; Schneider M
    Eur J Pharm Biopharm; 2020 Dec; 157():200-210. PubMed ID: 33222771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.